Shots:
- CE Mark was based on the P-III (PANOVA-3) trial assessing Optune Pax used concomitantly with gem/nab-pac (n=285), vs CT alone (n=286) in 571 adults with locally advanced pancreatic cancer, with launch expected in Germany in coming wks.
- Trial improved mOS to 16.2 vs 14.2mos. in ITT, with 1yr. survival of 68.1% vs 60.2%. In mITT (198 received Optune Pax + CT for ≥28 days vs 207 received ≥1 CT cycle), mOS was 18.3 vs 15.1mos., with 1yr. survival of 75.2% vs 65.9%
- Optune Pax + CT extended median time to pain progression to 15.2 vs 9.1mos.; QoL (EORTC QLQ-C30/PAN26) showed longer DFS in global health, pain, pancreatic pain, digestive issues, with similar trends in emotional function & fatigue, while other 2EPs showed no significant difference. Data published in The JCO
Ref: Businesswire | Image: Novocure | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
